a manufacturing capability recognized by global standards
FHL’s DNA is rooted in rigorous scientific discovery and work in the clinic.
Our Therapeutics drug development program adheres to exacting guidelines for formulation, clinical trial design and execution, and regulatory process. Consistent with the investigative rigor of our Therapeutics division, FHL Aesthetics’ product offering is anchored by our medical-grade Hyaluronic Acid filler solutions - among the earliest developed in Korea.
FHL has accumulated a decade's base of technical expertise related to clinical research, development and global distribution of medical-grade devices - knowledge and standards we apply to all products within our innovative medical- and cosmetic-grade aesthetics portfolio.
Processes and Standards
FHL’s innovative products are manufactured by
Optimized for Product Safety
Our optimized manufacturing process and clean-room environment are critical factors that result in a safe and long-duration sodium hyaluronate filler product.
FHL Korea strictly adheres to GMP guidelines governing the production of safe, stabilized, high-purity medical devices
Medical devices production employs high-purity, safe raw materials
syringe manufacturing facilities
We take immense pride in our experience and knowledge in rapidly
manufacturing and supplying superior medical devices.
FHL Korea was incorporated in 2013 and our production
facilities completed construction in 2015.
Given increasing global demand, capacity will double in 2023 to the equivalent of 6mm 1mL glass syringes.